Durable Response Seen With Axi-Cel in Non-Hodgkin Lymphoma
In this population, median progression-free survival was nearly 40 months.
CAR T-Cell Therapy's Continued Benefit in B-Cell Non-Hodgkin Lymphoma
Positive data has been seen with CAR T-cell therapy in patients with indolent lymphoma.
Investigating CAR T-Cell Therapies in Indolent Lymphoma
Longer follow-up is needed to determine the potential of CAR T-cell therapies in difficult-to-treat malignancies.
bb21217 Continues to Yield Improved, Durable Responses in Multiple Myeloma
The enriched chimeric antigen receptor T-cell therapy improved responses and prolonged duration of response in patients with relapsed/refractory multiple myeloma.
bb21217 Continues to Showcase Durable Responses in Multiple Myeloma
December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.
JNJ-4528 Continues to Show Durable Responses in Relapsed/Refractory Multiple Myeloma
The CAR T-cell therapy continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Updated CARTITUDE-1 Results Continue to Demonstrate Safety, Durable Responses for JNJ-4528 in R/R Multiple Myeloma
The chimeric antigen receptor T-cell therapy, JNJ-4528, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to updated findings from the phase 1b/2 CARTITUDE-1 (NCT03548207) trial.
Positive Safety Profile Reported for Atezolizumab/Axi-Cel Combo in DLBCL
A manageable safety profile was observed for the combination of atezolizumab and the anti-CD19 chimeric antigen receptor T-cell therapy, axicabtagene ciloleucel, in patients with refractory diffuse large B-cell lymphoma.
Survival Improved With Surgery/Targeted Therapy Combo in Renal Cell Carcinoma
Patients with renal cancer who underwent cytoreductive nephrectomy and targeted therapy had improved survival compared with patients who did not undergo the surgery.
Capmatinib Trial Targets New Molecular Subsets of Patients in NSCLC
An ongoing phase II, four-cohort trial involving
capmatinib (INC280), an oral MET inhibitor,
will determine the clinical activity of the agent
in pretreated patients with advanced non-small cell lung cancer
who have undergone one or two lines of therapy.
Expert Predicts PD-1/PD-L1 Agents as Backbone of Combination Therapy in RCC
PD-1 and PD-L1 inhibitors, including nivolumab, atezolizumab, and avelumab, will likely play a major role as the backbone of combination therapy for patients with renal cell carcinoma (RCC).
2 Clarke Drive Cranbury, NJ 08512